First COVID-19 sub-intensive respiratory unit in Europe: the Italian experience

First COVID-19 sub-intensive respiratory unit in Europe: the Italian experience

Authors

  • Sonia Henchi Pulmonary Medicine Unit, Lodi General Hospital, Lodi https://orcid.org/0000-0003-0364-8403
  • Clara Benedetta Conti Gastroenterology and Digestive Endoscopy Unit, Local Health Agency, Cremona https://orcid.org/0000-0001-9774-2374
  • Nicolò Vanoni Pulmonary Medicine Unit, Lodi General Hospital, Lodi https://orcid.org/0000-0002-4598-7131
  • Alice Claudia Repossi Pulmonary Medicine Unit, Lodi General Hospital, Lodi
  • Giuseppe Cipolla Pulmonary Medicine Unit, Lodi General Hospital, Lodi https://orcid.org/0000-0001-5097-5250
  • Mirko Marra School of General Practitioner, ATS Milano Città Metropolitana, Milan
  • Elena Esposti School of General Practitioner, ATS Milano Città Metropolitana, Milan
  • Michela Fiini Cardiology Unit, Lodi General Hospital, Lodi
  • Irene Raimondi Cominesi Cardiology Unit, Lodi General Hospital, Lodi
  • Monica Crepaldi Pulmonary Medicine Unit, Lodi General Hospital, Lodi
  • Mariano Scozzafava Pulmonary Medicine Unit, Lodi General Hospital, Lodi https://orcid.org/0000-0003-4706-7352

Keywords:

COVID-19, severe pneumonia, sub-intensive respiratory unit, department organization, ARDS, ventilation

Abstract

European SARS-CoV-2 pandemic epicenter was detected in Northern Italy, in a little Italian town of Lodi province, the Lodi Hospital was therefore rapidly saturated, and in particularly the departments of respiratory diseases and Intensive Care Unit had been largely involved. In this paper, we describe how the first Sub-intensive Respiratory Unit in Europe completely dedicated to COVID-19 patients was organized and managed in our hospital. From February 25th to April 30th 2020, 156 patients were admitted to our Respiratory Sub-intensive Unit. Among them, 100 were discharged, 28 dead and 28 transferred to ICU for intubation.

References

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74. doi: 10.1016/S0140-6736(20)30251-8.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CG, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20. doi: 10.1056/NEJMoa2002032

Paglia S, Storti E, Magnacavallo A, Cianci V. Rapporto prima linea Covid-19. Assetto organizzativo gestionale dei PS/DEA nell’ambito di focolaio epidemico o pre-epidemico. Available from: https://www.simeu.it/w/articoli/leggiArticolo/3964/leggi

Singer P, Blaser AR, Berger MM, Alhazzani W, Calder PC, Casaer MP, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr 2019;38:48-79. doi: 10.1016/j.clnu.2018.08.037

Walkey AJ, Del Sorbo L, Hodgson CL, Adhikari NKJ, Wunsch H, Meade MO, et al. Higher PEEP versus lower PEEP strategies for patients with acute respiratory distress syndrome. A systematic review and meta-analysis. Ann Am Thorac Soc 2017;14:S297-303. doi: 10.1513/AnnalsATS.201704-338OT

Fan E, Brodie D, Slutsky AS. Diagnosis and treatment in acute respiratory distress syndrome-reply. JAMA 2018;320:306. doi: 10.1001/jama.2018.5932.

Kalett RH. A comprehensive review of prone position in ARDS. Respir Care 2015;60:1660-87. doi: 10.4187/respcare.04271.

Bein B, Bachmann M, Huggett S, Wegermann P. SARS CoV-2/COVID-19: Evidence-based recommendation on diagnosis and therapy. Anasthesiol Intensivmed Notfallmed Schmerzther 2020;55:257-65.

Thomas AJ. Physiotherapy led early rehabilitation of the patient with critical illness. Phys Ther Rev 2011;16:46-57.

Wang T, Chen R, Liu C, Liang W, Guan W, Tang R, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol 2020;7:e3623. doi: 10.1016/S2352-3026(20)30109-5

Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020. doi: 10.1111/jth.14830.

Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020;19:149-50. doi: 10.1038/d41573-020-00016-0.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382:1787-99. doi: 10.1056/NEJMoa2001282.

Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020:10593. doi: 10.1016/j.ijantimicag.2020.105938.

Zhang Y, Zhong Y, Pan L, Dong J. Treat 2019 novel coronavirus COVID-19) with IL-6 inhibitor: Are we already that far? Drug Discov Ther 2020;142:100-2. doi: 10.5582/ddt.2020.03006.

Downloads

Published

23-06-2020

Issue

Section

Letters to the Editor

How to Cite

1.
Henchi S, Conti CB, Vanoni N, Repossi AC, Cipolla G, Marra M, et al. First COVID-19 sub-intensive respiratory unit in Europe: the Italian experience. Multidiscip Respir Med [Internet]. 2020 Jun. 23 [cited 2024 Jul. 4];15. Available from: https://mrmjournal.org/index.php/mrm/article/view/682